Are Bacteria a Secret Weapon Against Eczema?

NIH study suggests a potentially cheap and effective treatment for a painful condition.

Inflammation, itching, painful skin lesions: This is everyday life for patients with atopic dermatitis, a type of eczema that affects roughly 11 percent of adults and 7 percent of children in the United States and accounts for nearly $5.3 billion in annual health care costs. Topical steroids, usually hydrocortisone ointments, are often the first line of defense against eczema. The list price for a jar of such ointment can exceed $100—and it usually needs to be applied daily.

“Living with atopic dermatitis can be physically and emotionally challenging,” Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a statement. “Currently available therapies can be time-consuming—requiring multiple daily applications—and costly.”

Indeed, skincare companies target eczema patients with expensive lotions, oils, and other products. Even within the health care industry, a 2017 study found, outpatient care and prescription costs add up to thousands of dollars each year for patients with atopic dermatitis.

Now, scientists have identified a potentially cheap and effective alternative: bacteria.

In an early-phase clinical trial at the National Institutes of Health, the bacterium Roseomonas mucosa reduced the severity of atopic dermatitis in adults and children. The bug, naturally present on human skin, was previously shown to improve symptoms in mice. The ongoing trial is the first time it has shown results in human patients.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin
    SkinBiotherapeutics Plc

    More articles like this

    SkinBiotherapeutics Plc

    Why we should all be eating a microbiome diet

    First, let’s briefly talk about the microbiome. The gut microbiome refers to the trillions of bacteria that live within our gastrointestinal tracts. If you were to collectively bunch them all up into a ball, it would weigh anywhere

    SkinBiotherapeutics Plc

    Microbiome-based therapy for eczema: On the horizon?

    Results of pre-clinical and early clinical trials conducted by investigators at the National Institutes of Health showing the effectiveness of using bacteria to treat eczema are paving the way for further study into the potential for microbiome-based therapy

    SkinBiotherapeutics Plc

    SkinBioTherapeutics plc achieved significant manufacturing scale up

    Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “The progress we’ve made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies in preparation for the human study.” SkinBioTherapeutics plc

    SkinBiotherapeutics Plc

    Protect your skin microbiome

    Like your gut, your skin also has a complex system of bacteria and fungi living on its surface. “It sounds weird and scary, but it’s actually good for you,” says Sarvenaz Zand, M.D., a dermatologist based in Mill